Analysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK) and Standard BioTools (LAB)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Scholar Rock Holding (SRRK – Research Report) and Standard BioTools (LAB – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scholar Rock Holding (SRRK)
In a report released today, Geoff Meacham from Citi maintained a Buy rating on Scholar Rock Holding, with a price target of $55.00. The company’s shares closed last Friday at $44.06, close to its 52-week high of $46.98.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
Scholar Rock Holding has an analyst consensus of Strong Buy, with a price target consensus of $51.70, a 16.9% upside from current levels. In a report issued on January 27, Bank of America Securities also maintained a Buy rating on the stock with a $50.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Standard BioTools (LAB)
In a report released today, Kyle Boucher from TD Cowen maintained a Hold rating on Standard BioTools, with a price target of $1.35. The company’s shares closed last Friday at $1.40.
Boucher has an average return of
According to TipRanks.com, Boucher is ranked #5255 out of 12040 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Standard BioTools with a $1.35 average price target, a -4.6% downside from current levels. In a report issued on January 15, TipRanks – xAI also reiterated a Hold rating on the stock with a $1.50 price target.
